Latest France News

Diamond Infraco’s takeover bid for Atlas Arteria remains fixed at A$5.10 per security and is now unconditional, urging securityholders to act before the June 25 closing date amid lingering asset sale uncertainties.

Electro Optic Systems (ASX:EOS) reports sustained demand driven by global conflicts, launches MARSS business in Europe, and updates 2026 revenue outlook with base business guidance of $240m to $270m.

Diamond Infraco has increased its takeover bid for Atlas Arteria to A$5.10 per security, marking a 17.78% premium over pre-offer prices and declaring the offer unconditional except for prescribed occurrences. The bidder urges securityholders to accept or sell on-market before the June 25 deadline.

Optiscan Imaging has reached the halfway recruitment milestone in its first in-human breast cancer study, advancing its regulatory and commercial ambitions with promising clinical data and expanded trial sites.

Vulcan Energy has secured financial close on its €2.2 billion Lionheart Project financing, unlocking funds to advance construction of Europe’s pioneering lithium hydroxide and renewable energy facility in the Upper Rhine Valley.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Little Green Pharma has secured Federal Court approval for its full acquisition of Cannatrek, marking a key milestone in expanding its global medicinal cannabis footprint. The scheme became effective on 25 May 2026, with implementation set for 1 June.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Eden Innovations appoints former European Parliament member Antanas Guoga to lead EdenShield’s push into European defence and critical infrastructure markets amid surging regional security spending.

Tanami Gold has launched a fully underwritten $70.5 million renounceable rights issue priced at 6 cents per share, aiming to finance its 50% stake in the Central Tanami Project. The offer is open to eligible shareholders across select jurisdictions and runs until 27 May 2026.

Atlas Arteria reported a resilient 2025 with 9.3% EBITDA growth and steady toll revenue, while its Board unanimously urged investors to reject IFM’s unsolicited takeover offer, citing undervaluation and onerous conditions.

Tanami Gold NL (ASX:TAM) is raising $70.5 million through a fully underwritten renounceable rights issue priced at $0.06 per share, a 34.78% discount to the last traded price, to finance development of its Central Tanami Project.